Table 6.
Assay of δ-ALA-D in liver, kidney, and brain of rats after treatment with compounds 5a–d and 10.
| Concentration (μM) | Compounds | ||||
|---|---|---|---|---|---|
| 5a | 5b | 5c | 5d | 10 | |
| Liver | |||||
| control | 4,79 ± 0.87 | 4.79 ± 0.87 | 4.79 ± 0.87 | 4.30 ± 0.74 | 4.30 ± 0.74 |
| 10 | 4.99 ± 0.84 | 2.59 ± 0.29 *** | 4.63 ± 0.82 | 4.50 ± 0.60 | 4.90 ± 0.58 |
| 50 | 4.87 ± 0.67 | 0.42 ± 0.13 *** | 4.31 ± 0.81 | 4.22 ± 0.78 | 4.71 ± 0.53 |
| 100 | 4.71 ± 0.89 | 0.07 ± 0.02 *** | 4.12 ± 0.90 | 3.54 ± 0.84 | 4.57 ± 0.62 |
| 500 | 4.46 ± 0.80 | 0.03 ± 0.01 *** | 3.88 ± 0.87 | 2.84 ± 0.57 | 3.97 ± 0.82 |
| Kidney | |||||
| control | 1.01 ± 0.12 | 1.01 ± 0.12 | 1.01 ± 0.12 | 0.98 ± 0.11 | 0.98 ± 0.11 |
| 10 | 1.17 ± 0.05 | 1.08 ± 0.05 | 1.10 ± 0.12 | 1.02 ± 0.11 | 0.96 ± 0.12 |
| 50 | 1.17 ± 0.07 | 0.99 ± 0.07 | 1.02 ± 0.12 | 0.96 ± 0.12 | 0.95 ± 0.10 |
| 100 | 1.09 ± 0.08 | 0.68 ± 0.12 ** | 0.99 ± 0.10 | 0.89 ± 0.12 | 0.84 ± 0.10 |
| 500 | 0.90 ± 0.08 | 0.24 ± 0.03 *** | 0.90 ± 0.07 | 0.72 ± 0.07 | 0.61 ± 0.12 * |
| Brain | |||||
| control | 0.30 ± 0.05 | 0.26 ± 0.05 | 0.30 ± 0.05 | 0.30 ± 0.05 | 0.30 ± 0.05 |
| 10 | 0.44 ± 0.09 | 0.30 ± 0.11 | 0.30 ± 0.10 | 0.29 ± 0.09 | 0.30 ± 0.10 |
| 50 | 0.42 ± 0.10 | 0.25 ± 0.05 | 0.28 ± 0.09 | 0.27 ± 0.10 | 0.28 ± 0.09 |
| 100 | 0.40 ± 0.11 | 0.18 ± 0.03 | 0.26 ± 0.08 | 0.26 ± 0.09 | 0.26 ± 0.08 |
| 500 | 0.36 ± 0.10 | 0.14 ± 0.04 | 0.26 ± 0.07 | 0.24 ± 0.08 | 0.26 ± 0.07 |
Notes: Data expressed mean ± SD (n = 3). The asterisks represent significant difference (**) p < 0.01; (***) p < 0.001 when compared with control sample by Student–Newman–Keuls test for post-hoc comparison.